心血管

订阅

MedSci主页 / 所有栏目 / 心血管

II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效

2019-02-18 不详 网络

Debio1347晚期实体瘤FUZE研究
关注

Debiopharm International SA是瑞士的全球生物制药公司Debiopharm集团的一部分，近日宣布已启动FUZE研究，这是一项II期临床研究，旨在评估Debio 1347治疗携带FGFR融合的实体瘤（NCT03834220）。

Debiopharm International SA是瑞士的全球生物制药公司Debiopharm集团的一部分，近日宣布已启动FUZE研究，这是一项II期临床研究，旨在评估Debio 1347治疗携带FGFR融合的实体瘤（NCT03834220）。

成纤维细胞生长因子受体（FGFR）基因的特异性改变（融合）解除了FGFR信号传导途径的限制，并驱动肿瘤细胞的过度生长。Debio 1347是一种有效的FGFR选择性抑制剂。该研究将招募患有晚期或转移性肿瘤的患者，其肿瘤细胞显示特异性的FGFR基因改变，即FGFR1、FGFR2或FGFR3基因融合。该试验的目的是证明Debio 1347可以为携带FGFR融合的肿瘤患者带来临床益处。

Debiopharm International SA集团医疗总监Claudio Zanna说：“FUZE临床试验是根据特定肿瘤的基因改变而不是根据肿瘤类型设计的。无论肿瘤类型如何，都可以使具有罕见遗传改变的癌症患者受益，例如FGFR融合。我们致力于采用先进技术指导的创新治疗方法来满足未被满足的医疗需求，旨在改善癌症患者的预后和生活质量”。


原始出处：

http://www.firstwordpharma.com/node/1625327#axzz5fc4uA1RS

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997107, encodeId=4498199e107cb, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 02 08:53:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Tue May 07 12:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Sep 24 16:53:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918545, encodeId=29ce191854509, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 31 00:53:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032072, encodeId=839c10320e20b, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 18 22:53:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-05-02 linagood

    #EBI#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1997107, encodeId=4498199e107cb, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 02 08:53:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Tue May 07 12:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Sep 24 16:53:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918545, encodeId=29ce191854509, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 31 00:53:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032072, encodeId=839c10320e20b, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 18 22:53:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-05-07 huiwelcome

    #II期临床研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1997107, encodeId=4498199e107cb, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 02 08:53:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Tue May 07 12:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Sep 24 16:53:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918545, encodeId=29ce191854509, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 31 00:53:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032072, encodeId=839c10320e20b, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 18 22:53:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-09-24 医生2402

    #I期临床#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1997107, encodeId=4498199e107cb, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 02 08:53:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Tue May 07 12:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Sep 24 16:53:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918545, encodeId=29ce191854509, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 31 00:53:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032072, encodeId=839c10320e20b, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 18 22:53:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-05-31 sunylz

    #Bio#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1997107, encodeId=4498199e107cb, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 02 08:53:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Tue May 07 12:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Sep 24 16:53:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918545, encodeId=29ce191854509, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 31 00:53:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032072, encodeId=839c10320e20b, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 18 22:53:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-02-20 446798725_87912766

    #晚期实体瘤#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1997107, encodeId=4498199e107cb, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 02 08:53:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Tue May 07 12:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Sep 24 16:53:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918545, encodeId=29ce191854509, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 31 00:53:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032072, encodeId=839c10320e20b, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 18 22:53:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-02-20 guihongzh

    #II期临床#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1997107, encodeId=4498199e107cb, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Thu May 02 08:53:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649984, encodeId=92bc1649984b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Tue May 07 12:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Sep 24 16:53:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918545, encodeId=29ce191854509, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri May 31 00:53:00 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Feb 20 10:53:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032072, encodeId=839c10320e20b, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 18 22:53:00 CST 2019, time=2019-02-18, status=1, ipAttribution=)]
    2019-02-18 内科新手

    谢谢梅斯提供这么好的信息，学到很多

    0